A low dose of TDF may help to preserve renal function and maintain viral suppression in patients with chronic hepatitis B virus infection, even those with advanced liver disease.
HRS-1 is a rare, acute complication of liver cirrhosis characterized by life-threatening and rapid progression that can end in renal failure. Terlipressin, a vasopressin analogue, could become the first therapy approved for the treatment of HRS-1 in the US.
At 12 weeks post treatment per protocol analysis with 8 weeks of glecaprevir/pibrentasvir treatment, patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response.
The use of mood-altering medications does not increase odds for hepatic encephalopathy or hepatic encephalopathy-related hospital admissions after TIPS placement, according to the results of a new study.
Although acute kidney injury is common in patients with cirrhosis, those who are admitted to the hospital are at increased risk, especially if they are of older age, Child-Pugh Class C, or have ascites or sepsis.
Data from a phase 2, double-blind, placebo-controlled study, showed a higher dose of simvastatin was associated with greater liver and muscle toxicity compared with a lower dose for patients with decompensated cirrhosis.
Obese patients who underwent weight-loss surgery prior to receiving a liver transplant had a significantly lower risk of metabolic complications post-transplant than those who followed medical weight loss prior to transplant.
The first results of a study on the use of monthly RNAi with ARO-HBV in patients with chronic hepatitis B virus infections indicate that the treatment effectively reduced all measurable viral products, including HBsAg.
In the effort to help the growing number of people with liver disease new medications are constantly being developed. This is true for a wide range of conditions including cirrhosis and fibrosis.
A considerable amount of research has been done looking at how liver disease can progress in patients, but a recent study looked at possible regression in conditions like cirrhosis and fibrosis.
In the past, patients deemed obese (especially those who were morbidly obese) may have been passed over for a life-saving liver transplant. A recent study showed they may be just as viable candidates for the procedure as others in the patient population.